← Leaderboards
C Ronald Scott
University Of Washington
$29,536
Attributed
$29,536
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $18.5K · FY2005–06$20K$15K$10K$5K$0
'05
'06
Funding mix
By agency
NIH$29,536 · 2
By mechanism
M01$29,536 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Stuart Shankland$30,345,727
- David Chandler Dale$13,804,610
- Bonnie W Ramsey$21,623,756
- Evan E. Eichler$97,393,877
- Debbie S Gipson$9,175,721
Others in their field
Top investigators on “Alpha Galactosidase”
- Cheryl Louise Stucky · Medical College Of Wisconsin$4,767,055
- Yu-Teh Li · Tulane University Of Louisiana$3,113,466
- Luc Teyton · Scripps Research Institute, The$2,916,161
- Ervin H Epstein · University Of California San Francisco$2,732,941
- Nancy M. Dahms · Medical College Of Wisconsin$2,662,492
- James Alan Shayman · University Of Michigan At Ann Arbor$2,450,889
Research focus
Alpha GalactosidaseClinical ResearchEnzyme TherapyFabry'S DiseaseGenetic DisorderHuman SubjectHuman Therapy EvaluationPatient Oriented ResearchKidney FunctionBiological ProductsBiotherapeutic AgentHuman Genetic Material TagDrug HypersensitivityDrug Screening /EvaluationSex Linked TraitRecombinant Proteins
Grant awards (4)
SAFETY AND EFFICACY STUDY OF FABRAZYMER IN PATIENTS WITH FABRY DISEASE$5,788
M01 · FY2006 · RR · contact PI
SAFETY AND EFFICACY STUDY OF FABRAZYMER IN PATIENTS WITH FABRY DISEASE$18,543
M01 · FY2005 · RR
Cautious graded rechallenge with intravenous r-h alph$3,036
M01 · FY2004 · RR
Safety and efficacy study of Fabrazyme in patients with Fabry Disease$2,169
M01 · FY2004 · RR